Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Scribe Therapeutics, Inc. (SCTX)

Scribe Therapeutics Q2 net loss narrows to $6.5 million as revenue falls to $1.9 million

Mixed Impact 3 of 5 earnings Written later

Scribe Therapeutics reported second quarter 2026 results for the period ended June 30, 2026. Net loss narrowed to $6.5 million from $9.9 million a year earlier, but collaboration revenue fell to $1.9 million from $4.9 million. The company said its July 2026 IPO and concurrent Sanofi private placement, with about $140.6 million of net proceeds, extend its funding into the first half of 2029.

Key points

  • Net loss of $6.5 million, or $2.62 per share, versus $9.9 million, or $4.08 per share, a year earlier
  • Collaboration revenue of $1.9 million versus $4.9 million; research and development expenses of $8.8 million versus $13.9 million
  • Cash, cash equivalents and marketable securities of $43.0 million at June 30, 2026, plus about $140.6 million of net IPO and private placement proceeds

The filing

CompanyScribe Therapeutics, Inc. (SCTX)
Form8-K, current report
Filed with the SECSep 2, 2026, 4:08 PM ET
Accession number0001193125-26-380184

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.